Page 31 - Aadi Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) — Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreeme...

Share this article Share this article NEW YORK, May 19, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerpio Pharmaceuticals, Inc. ("Aerpio" or the "Company") (NASDAQ: ARPO) in connection with the proposed merger of the Company with privately-held Aadi Bioscience, Inc. ("Aadi"). Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will trade publicly on the NASDAQ. At close of the transac...

(1) LAS VEGAS, March 4, 2021 /PRNewswire/ -- Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year. However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of cli...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 ... Aadi Bioscience Inc.January 11, 2021 GMT Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties PACIFIC PALISADES, CALIFORNIA and SHANGHAI...